GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XTER:GIS) » Definitions » E10

Gilead Sciences (XTER:GIS) E10 : €5.23 (As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Gilead Sciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Mar. 2025 was €0.962. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €5.23 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Gilead Sciences's average E10 Growth Rate was -9.00% per year. During the past 3 years, the average E10 Growth Rate was 1.00% per year. During the past 5 years, the average E10 Growth Rate was 4.50% per year. During the past 10 years, the average E10 Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Gilead Sciences was 85.40% per year. The lowest was 1.00% per year. And the median was 22.90% per year.

As of today (2025-06-26), Gilead Sciences's current stock price is €90.80. Gilead Sciences's E10 for the quarter that ended in Mar. 2025 was €5.23. Gilead Sciences's Shiller PE Ratio of today is 17.36.

During the past 13 years, the highest Shiller PE Ratio of Gilead Sciences was 50.11. The lowest was 9.93. And the median was 13.75.


Gilead Sciences E10 Historical Data

The historical data trend for Gilead Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences E10 Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.99 5.06 5.73 5.98 5.67

Gilead Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.77 5.69 5.38 5.67 5.23

Competitive Comparison of Gilead Sciences's E10

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.


;
;

Gilead Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.962/134.9266*134.9266
=0.962

Current CPI (Mar. 2025) = 134.9266.

Gilead Sciences Quarterly Data

per share eps CPI Adj_EPS
201506 2.602 100.684 3.487
201509 2.726 100.392 3.664
201512 2.919 99.792 3.947
201603 2.272 100.470 3.051
201606 2.296 101.688 3.046
201609 2.219 101.861 2.939
201612 2.218 101.863 2.938
201703 1.917 102.862 2.515
201706 2.074 103.349 2.708
201709 1.728 104.136 2.239
201712 -2.501 104.011 -3.244
201803 0.949 105.290 1.216
201806 1.190 106.317 1.510
201809 1.371 106.507 1.737
201812 0.002 105.998 0.003
201903 1.363 107.251 1.715
201906 1.301 108.070 1.624
201909 -0.835 108.329 -1.040
201912 1.908 108.420 2.374
202003 1.104 108.902 1.368
202006 -2.362 108.767 -2.930
202009 0.246 109.815 0.302
202012 1.011 109.897 1.241
202103 1.151 111.754 1.390
202106 1.004 114.631 1.182
202109 1.743 115.734 2.032
202112 0.266 117.630 0.305
202203 0.018 121.301 0.020
202206 0.861 125.017 0.929
202209 1.434 125.227 1.545
202212 1.227 125.222 1.322
202303 0.747 127.348 0.791
202306 0.766 128.729 0.803
202309 1.621 129.860 1.684
202312 1.045 129.419 1.089
202403 -3.073 131.776 -3.146
202406 1.198 132.554 1.219
202409 0.901 133.029 0.914
202412 1.356 133.157 1.374
202503 0.962 134.927 0.962

Add all the adjusted EPS together and divide 10 will get our e10.


Gilead Sciences  (XTER:GIS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gilead Sciences's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=90.80/5.23
=17.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Gilead Sciences was 50.11. The lowest was 9.93. And the median was 13.75.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gilead Sciences E10 Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).